Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Novo Nordisk A/S NVO reported fourth-quarter 2024 earnings of 91 cents per American Depositary Receipt (ADR), which beat the ...

Studies have suggested that GLP-1RAs may show promise for a host of conditions, from alcohol use disorder to Parkinson’s. But ...

and fast-acting insulin Humalog. And that's before we get into the company's pipeline, which features plenty of investigational drugs beyond Eli Lilly's core area of diabetes and obesity.

Eli Lilly’s big-selling insulin, Humalog, faces cut-price competition after the US regulator approved a biosimilar from Sanofi. Sanofi’s Admelog (insulin lispro) is approved in type 1 and type ...

Indianapolis-based drugmaker Eli Lilly ... insulin – and Humulin (insulin human) injection 100 units/mL, by 70%, effective as of Q4 2023. Both Humalog and Insulin Lispro Injection are fast ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...